Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) -

Status Completed

Clinical Trial Summary

The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials. Safety endpoints will be compared following an alcohol challenge without and concurrent with BXCL501 treatment.

Clinical Trial Description

BXCL501 is a sublingual film containing dexmedetomidine. Dexmedetomidine is an alpha-2 adrenergic receptor agonist and has higher intrinsic activity and is more potent in vitro than either clonidine or lofexidine. The drug has a high free brain to free plasma ratio after dosing in rats that persists after plasma concentrations are cleared. Dexmedetomidine does not depress respiratory function. It is not predicted to have abuse potential. BXCL501 will bypass 1st pass metabolism and produce fewer problems in participants with compromised liver function. This laboratory study is a phase 1, double-blind, placebo-controlled, within subjects study. This study will consist of 3 laboratory test sessions following pretreatment with BXCL501/placebo for 10 heavy drinker participants with comorbid PTSD. Participants (n=10) will participate in a laboratory study with 3 test days (minimum of 2 days, but no longer than 2 weeks between each test session); for each test day they will be assigned to receive sublingual BXCL501 40µg, 80µg and placebo in a randomized fashion. Test sessions will be conducted to evaluate stress (PTSD) reactivity and alcohol cue reactivity. Participants will also receive IV ethanol administered via "clamp methodology" to assess for the effects of BXCL501 in combination with ethanol. Since this is the first time BXCL501 is being tested in combination with alcohol administration, the study team will be using a modified randomization where participants will not receive the 80µg dose until they have received the 40µg dose. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04827056
Study type	Interventional
Source	Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Contact
Status	Completed
Phase	Phase 1
Start date	November 9, 2021
Completion date	June 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04927364` - Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder	N/A
Active, not recruiting	`NCT04618653` - Comprehensive Process Model of AA-related Behavior Change
Recruiting	`NCT05471154` - Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders	N/A
Completed	`NCT05021640` - Study of DCR-AUD in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT05064228` - Mobile Rewarding Activity Centered Treatment	N/A
Completed	`NCT04958655` - Mental Imagery Intervention for Alcohol Craving	N/A
Completed	`NCT05252221` - Alcohol Telemedicine Consultation in Primary Care (ATC)	N/A
Completed	`NCT06108115` - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder	N/A
Not yet recruiting	`NCT06303778` - Combining a Smartphone App With Medications to Manage Heavy Drinking	N/A
Completed	`NCT04639895` - Cognitive Rehabilitation Through Personalized Virtual Reality and Paper-and-pencil Interventions in the Alcohol Use Disorder Treatment.	N/A
Completed	`NCT02911285` - NAC for Treating Comorbid PTSD and SUD	Phase 2
Recruiting	`NCT04598399` - Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder	N/A
Completed	`NCT04974645` - Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use	N/A
Recruiting	`NCT05992272` - Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
Completed	`NCT04229095` - Medication Development in Alcoholism: Suvorexant Versus Placebo	Phase 2
Recruiting	`NCT05534568` - The Oklahoma Parent-Child Assistance Program	N/A
Completed	`NCT04925570` - The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use	Phase 2
Active, not recruiting	`NCT05492942` - Records for Alcohol Care Enhancement	N/A
Recruiting	`NCT05015881` - Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder	Phase 2/Phase 3
Completed	`NCT05120856` - AAT-App Outpatient Trial	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms